Literature DB >> 15197780

Expression of the tyrosine kinase c-kit is an independent prognostic factor in patients with small cell lung cancer.

Ulrich-Peter Rohr1, Nina Rehfeld, Lucy Pflugfelder, Helene Geddert, Wolfram Müller, Ulrich Steidl, Roland Fenk, Thorsten Gräf, Matthias Schott, Klaus-Peter Thiele, Helmut Erich Gabbert, Ulrich Germing, Ralf Kronenwett, Rainer Haas.   

Abstract

In a retrospective analysis of 203 patients with small cell lung cancer (SCLC), we examined the prognostic value of c-kit expression on survival. Expression of c-kit was examined immunohistochemically in formalin-fixed, paraffin-embedded tissue sections. c-kit was observed in 87.7% of SCLC tumors. Using the Kaplan-Meier model, we found that lack of c-kit expression was associated with significantly shorter survival time compared to the presence of c-kit expression (mean survival 151 +/- 27 vs. 358 +/- 49 days, p = 0.0084). Moreover, the proportion of c-kit(+) cells within the tumor was also related to survival time. Patients with tumors in which >75% of cells stained positive for c-kit had a mean overall survival time of 424 (+/-72) compared to 295 (+/-67) days for patients with 25-75% c-kit(+) tumor cells. Patients with tumors containing <25% c-kit(+) cells had the worst survival, with 164 (+/-24) days (p = 0.0033). Further parameters associated with short survival times were low performance status, elevated levels of lactate dehydrogenase and higher stage according to the TNM classification. Multivariate analysis using the Cox regression model showed that the proportion of c-kit(+) cells within the tumor specimen was one of 3 independent prognostic parameters (p = 0.004) for overall survival next to TNM classification (p = 0.001) and performance status (p < 0.001). Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15197780     DOI: 10.1002/ijc.20252

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  16 in total

1.  An immunohistochemical and molecular genetic analysis of KIT and PDGFRA in small cell lung carcinoma in Japanese.

Authors:  Tadashi Terada
Journal:  Int J Clin Exp Pathol       Date:  2012-04-16

Review 2.  Genomics of lung cancer may change diagnosis, prognosis and therapy.

Authors:  László Kopper; József Tímár
Journal:  Pathol Oncol Res       Date:  2005-03-31       Impact factor: 3.201

3.  Changes in c-Kit expression levels during the course of radiation therapy for nasopharyngeal carcinoma.

Authors:  Feng Jiang; Wei Hu; Bicheng Zhang; Jing Xu; Yongjie Shui; Xiaofeng Zhou; Xiaoqiu Ren; Xiaozhong Chen; Li Shen; Qichun Wei
Journal:  Biomed Rep       Date:  2016-09-12

4.  CD117, Ki-67, and p53 predict survival in neuroendocrine carcinomas, but not within the subgroup of small cell lung carcinoma.

Authors:  Brian S Erler; Matthew M Presby; Meredith Finch; Allison Hodges; Kari Horowitz; Arthur A Topilow; Theodore Matulewicz
Journal:  Tumour Biol       Date:  2010-11-08

Review 5.  Targeted drugs in small-cell lung cancer.

Authors:  Mariacarmela Santarpia; Maria Grazia Daffinà; Niki Karachaliou; Maria González-Cao; Chiara Lazzari; Giuseppe Altavilla; Rafael Rosell
Journal:  Transl Lung Cancer Res       Date:  2016-02

Review 6.  Small cell lung cancer: where do we go from here?

Authors:  Lauren Averett Byers; Charles M Rudin
Journal:  Cancer       Date:  2014-10-21       Impact factor: 6.860

7.  Expression and mutational status of c-kit in thymic epithelial tumors.

Authors:  Iacopo Petrini; Paolo A Zucali; Hye Seung Lee; Marbin A Pineda; Paul S Meltzer; Beatriz Walter-Rodriguez; Massimo Roncalli; Armando Santoro; Yisong Wang; Giuseppe Giaccone
Journal:  J Thorac Oncol       Date:  2010-09       Impact factor: 15.609

8.  Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

Authors:  Lauren Averett Byers; Jing Wang; Monique B Nilsson; Junya Fujimoto; Pierre Saintigny; John Yordy; Uma Giri; Michael Peyton; You Hong Fan; Lixia Diao; Fatemeh Masrorpour; Li Shen; Wenbin Liu; Boris Duchemann; Praveen Tumula; Vikas Bhardwaj; James Welsh; Stephanie Weber; Bonnie S Glisson; Neda Kalhor; Ignacio I Wistuba; Luc Girard; Scott M Lippman; Gordon B Mills; Kevin R Coombes; John N Weinstein; John D Minna; John V Heymach
Journal:  Cancer Discov       Date:  2012-09-06       Impact factor: 39.397

9.  [Prognostic value of immunohistochemistry in salivary gland cancer].

Authors:  T Ettl; S Schwarz; T Kühnel; P Stockmann; T E Reichert; O Driemel
Journal:  HNO       Date:  2008-02       Impact factor: 1.284

10.  Prognostic value of CD117 in cancer: a meta-analysis.

Authors:  Fuyou Zhao; Yuqing Chen; Qiong Wu; Zian Wang; Jie Lu
Journal:  Int J Clin Exp Pathol       Date:  2014-02-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.